3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
3
Leukemia
2
Burkitt Lymphoma
2
Recurrence
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Bites and Stings
1
Interventions
fludarabine phosphate
3
Doxorubicin
3
Cytarabine
3
venetoclax
2
Vincristine
2
Mycophenolic Acid
2
Filgrastim
2
Dexamethasone
2
Cyclophosphamide
2
Calcium Dobesilate
2
pegaspargase
1
obatoclax
1
lirilumab
1
liposomal doxorubicin
1
ixazomib
1
fludarabine
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
Whole-Body Irradiation
1
Vorinostat
1
Tetradecanoylphorbol Acetate
1
Tacrolimus
1
Sunitinib
1
Razoxane
1
Radiotherapy
1
Platelet Transfusion
1
Peripheral Blood Stem Cell Transplantation
1
Oxycodone
1
Moxifloxacin
1
Morphine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Biphenotypic, Acute
×
blinatumomab
×
Clear all
NCT04044560
2022-02-21
OZM-097
University of British Columbia
Phase 2
Terminated
8 enrolled